Xeris Biopharma appoints Menassie Taddese to board, expanding it to nine members
Xeris Biopharma Holdings appointed Menassie Taddese as a director effective November 2, 2026, increasing the board from eight to nine members and placing him on the Audit Committee. The filing describes his prior roles at Viatris and Pfizer and states the board considers him independent under Nasdaq standards.
Key points
- Effective November 2, 2026; Taddese is a Class II director with a term expiring at the 2029 annual meeting
- Board increased from eight to nine members; Taddese also joins the Audit Committee
- Initial equity award with a grant date fair value of approximately $450,000; annual grant of about $300,000 eligible from the 2027 annual meeting
- Previously served as President, Emerging Markets at Viatris (November 2020 to December 2022) and held roles at Pfizer from 1997 to 2020
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.